Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Standards For Molecular Imaging Agents Can Vary, Panel Tells FDA

Executive Summary

The evidence needed to show efficacy and utility of a molecular imaging agent depends on what is being scanned and what claim is being sought, FDA's Peripheral and Central Nervous System Drugs Advisory Committee advised the agency Aug. 11

You may also be interested in...



Alzheimer’s Imaging Agents Should Be Validated With Autopsies, Panel Says

Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded

Nycomed Datscan Can Distinguish Parkinson's From Tremor - CPMP

Nycomed Amersham's nuclear imaging agent Datscan has been recommended to distinguish Parkinson's disease from other disorders by the European Medicines Evaluation Agency's Committee for Proprietary Medicinal Products.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel